# Eleven Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eleven-therapeutics

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Website: www.eleventx.com
- Total disclosed funding: $22M
- Latest round: Seed (Aug 2, 2022)
- Investors on record: 6

## About

Based in Tel Aviv, Israel, and founded in 2020, by Prof. Yaniv Erlich, Shaul Ilan, and Prof. Greg Hannon, Eleven Therapeutics Ltd., aka Eleven Therapeutics, operates as a biotechnology company that primarily offers a combination of chemistry and artificial intelligence (AI) for RNA interference (RNAi) drug development. In August 2022, Eleven Therapeutics Ltd. raised USD 22 million in a Seed funding led by Bill & Melinda Gates Foundation Trust, with participation from Entrée Capital, Harel Insurance Investments, Innovate UK, Kindred Capital, and NFX.

Eleven Therapeutics offers SCSI-RNA, a programmable molecule used for analyzing diseases or biological targets of interest, as well as generating functional data about the activity profile of an unprecedented scale of siRNA (small interfering RNAs) molecules. The company also offers TERÅ beads (topologically encoded, RNA-active) platform to boost the performance of oligonucleotide therapeutics by creating DNA barcodes on each bead that record the pattern of these RNA modifications and make them available to high throughput sequencing.

## Funding rounds

- Seed, Aug 2, 2022, $22M — Gates Foundation Trust, Harel Insurance Investments, Entree Capital, Innovate UK, Kindred Capital, NFX

## Investors

- Gates Foundation Trust — Seed
- Harel Insurance Investments — Seed
- Entree Capital (https://capitalatlas.ai/funds/entree-capital) — Seed
- Innovate UK — Seed
- Kindred Capital (https://capitalatlas.ai/funds/kindred-capital) — Seed
- NFX (https://capitalatlas.ai/funds/nfx) — Seed